JPS6157284B2 - - Google Patents
Info
- Publication number
- JPS6157284B2 JPS6157284B2 JP2986880A JP2986880A JPS6157284B2 JP S6157284 B2 JPS6157284 B2 JP S6157284B2 JP 2986880 A JP2986880 A JP 2986880A JP 2986880 A JP2986880 A JP 2986880A JP S6157284 B2 JPS6157284 B2 JP S6157284B2
- Authority
- JP
- Japan
- Prior art keywords
- cystine
- allyl
- sulfoxide
- administration
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 7
- 208000019423 liver disease Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 38
- 238000002474 experimental method Methods 0.000 description 21
- 241000700159 Rattus Species 0.000 description 18
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 12
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 206010067125 Liver injury Diseases 0.000 description 8
- 231100000234 hepatic damage Toxicity 0.000 description 8
- 230000008818 liver damage Effects 0.000 description 8
- 230000003449 preventive effect Effects 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 208000006454 hepatitis Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 206010008909 Chronic Hepatitis Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000002075 main ingredient Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 244000245420 ail Species 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000015115 caffè latte Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2986880A JPS56127312A (en) | 1980-03-10 | 1980-03-10 | Drug for remedy of hepatic disease and recovery from fatigue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2986880A JPS56127312A (en) | 1980-03-10 | 1980-03-10 | Drug for remedy of hepatic disease and recovery from fatigue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56127312A JPS56127312A (en) | 1981-10-06 |
| JPS6157284B2 true JPS6157284B2 (enrdf_load_stackoverflow) | 1986-12-06 |
Family
ID=12287942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2986880A Granted JPS56127312A (en) | 1980-03-10 | 1980-03-10 | Drug for remedy of hepatic disease and recovery from fatigue |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56127312A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0292030U (enrdf_load_stackoverflow) * | 1989-01-10 | 1990-07-20 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102016117961A1 (de) | 2016-09-23 | 2018-03-29 | Dr. Ing. H.C. F. Porsche Aktiengesellschaft | Abgassystem eines verbrennungstechnisch betriebenen Kraftfahrzeugs mit Turbolader |
-
1980
- 1980-03-10 JP JP2986880A patent/JPS56127312A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0292030U (enrdf_load_stackoverflow) * | 1989-01-10 | 1990-07-20 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56127312A (en) | 1981-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1149255A (zh) | 镁基产品用于治疗或预防肿瘤和自体免疫疾病的用途 | |
| JP3074519B2 (ja) | 腸液吸収促進剤 | |
| JP2972343B2 (ja) | スッポンとカメの組成物 | |
| JPS6157284B2 (enrdf_load_stackoverflow) | ||
| CN112138148B (zh) | 一种生长激素或其类似物的口服药物组合物 | |
| RU2283114C1 (ru) | Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы | |
| CN104784192B (zh) | 蚌肉寡糖在制备降血糖药物中的应用及其制备方法 | |
| RU2390348C1 (ru) | Средство "стабинорм" для лечения синдрома хронической усталости | |
| CN112972658B (zh) | 一种生长激素或其类似物的口服药物组合物 | |
| RU2061475C1 (ru) | Лекарственное средство, стимулирующее эритроидный росток кроветворения при цитостатических миелодепрессиях | |
| CN114042083B (zh) | 四硫代钼酸盐的增肌及治疗应用 | |
| CN108404016A (zh) | 一种蒙兽药及其在抗动物冷应激中的应用 | |
| CN117838829B (zh) | 一种改善炎症关联性疲劳的中药组合物 | |
| RU2256460C2 (ru) | Способ лечения неспецифической бронхопневмонии у телят | |
| KR100732614B1 (ko) | 복어 추출물을 포함하는 비만 또는 당뇨성 질환의 예방또는 치료용 약학 조성물 | |
| JP2003507334A (ja) | 血漿代用組成物 | |
| Clifford et al. | Dimethyl myleran therapy combined with abdominal aortic occlusion | |
| CN110787287B (zh) | 一种鱼鳞胶原蛋白多肽在制备治疗慢性心力衰竭药物中的应用 | |
| RU2337698C1 (ru) | Противодиабетическое средство с гиполипидемической активностью для лечения и профилактики сахарного диабета ii типа | |
| WO1999016456A1 (en) | Biologically active preparation, complex of such preparations and immuno-stimulation method | |
| CN100446791C (zh) | 一种治疗出血性脑挫裂伤的中药组合物 | |
| RU2131739C1 (ru) | Сбор, обладающий антидиабетическим действием "ная" | |
| CN100435825C (zh) | 知母提取物在制备防、治原发性高血压药物中的应用 | |
| RU2673555C2 (ru) | Способ применения "Ягель детокс" в качестве средства для лечения туберкулеза с множественной лекарственной устойчивостью | |
| RU2308956C2 (ru) | Способ профилактики осложнений химиотерапии при лечении онкологического заболевания |